Amorfix Promises Update on Blood Test Diagnostic for ALS at the MND/ALS 24th International Symposium

In January, Amorfix Life Sciences announced they were developing a blood test that could be used to diagnose ALS, building on their initial findings that showed that ALS patients have misfolded SOD1 circulating in their blood. The “simple and rapid blood test” diagnostic will utilize Amorfix’s “proprietary antibodies” that can detect misfolded SOD1 with the hopes of identifying “patients with early-stage disease” and providing patients earlier access to potential treatments through clinical trials. Amorfix has promised an update on the development of this blood test diagnostic at the upcoming 24th Annual International Symposium on MND/ALS, which will be held in Milan, Italy, December 6-8, 2013. Planning to attend ALS/MND this year so that you can learn about the latest research findings in ALS? July 28th is the last day to get the Early Bird registration rate.

In January, Amorfix Life Sciences announced they were developing a blood test that could be used to diagnose ALS, building on their initial findings that showed that ALS patients have misfolded SOD1 circulating in their blood. The “simple and rapid blood test” diagnostic will utilize Amorfix’s “proprietary antibodies” that can detect misfolded SOD1 with the hopes of identifying “patients with early-stage disease” and providing patients earlier access to potential treatments through clinical trials. Amorfix has promised an update on the development of this blood test diagnostic at the upcoming 24th Annual International Symposium on MND/ALS, which will be held in Milan, Italy, December 6-8, 2013. Planning to attend ALS/MND this year so that you can learn about the latest research findings in ALS? July 28th is the last day to get the Early Bird registration rate.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail